Uso y duración de terapia antibiótica en la exacerbación pulmonar aguda de la fibrosis quística: un tema aún sin definir
DOI:
https://doi.org/10.35839/repis.6.3.1440Palabras clave:
fibrosis quística, antibacterianos, brote de los síntomas, enfermedades pulmonares, literatura de revisión como asuntoResumen
La fibrosis quística es una enfermedad sobre la que aún no se sabe mucho y sigue siendo un tema candente en la medicina traslacional y pulmonar. La evidencia sobre el manejo de las exacerbaciones es limitada, con pocos ensayos clínicos y revisiones sistemáticas. Por ejemplo, se desconoce el uso y la duración de los antibióticos en esta enfermedad. Teniendo en cuenta que se trata de una enfermedad que supone un elevado coste sanitario y que disminuye sustancialmente la capacidad funcional del afectado, es necesario establecer rápidamente algoritmos prácticos basados en la evidencia. En base a lo anterior, el objetivo de esta revisión narrativa es sintetizar evidencia sobre el uso y la duración del tratamiento antibiótico en las exacerbaciones pulmonares agudas en pacientes con fibrosis quística. Para esto, se llevó a cabo una búsqueda bibliográfica en los motores de búsqueda y bases de datos bases de datos PubMed, ScienceDirect, Embase, EBSCO y MEDLINE. Se definió que cualquier artículo relacionado con la evaluación del uso y duración de antibioticoterapia en la exacerbación aguda pulmonar del paciente con fibrosis quística, sería incluido, dando prioridad a los estudios originales y a las revisiones sistemáticas y meta-análisis. Posterior a la revisión del título y resumen de todos los resultados, se incluyeron 42 artículos. Se encontró que instaurar antibioticoterapia 10 días posterior al tratamiento estándar, por vía intravenosa, ya sea de doxiciclina o azitromicina más colistimetato, permite obtener mayor recuperación de la función pulmonar perdida, alargar el tiempo hasta la próxima exacerbación y solucionar sintomatología rápidamente.
Descargas
Citas
Goss CH. Acute Pulmonary Exacerbations in Cystic Fibrosis. Semin Respir Crit Care Med. 2019; 40(6):792-803. doi: 10.1055/s-0039-1697975
Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros. 2015; 14(4):419-30. doi: 10.1016/j.jcf.2015.03.003
Turcios NL. Cystic Fibrosis Lung Disease: An Overview. Respir Care. 2020; 65(2):233-251. doi: 10.4187/respcare.06697
Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012; 40(1):61-6. doi: 10.1183/09031936.00159111
Sagel SD, Thompson V, Chmiel JF, Montgomery GS, Nasr SZ, Perkett E, et al. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Ann Am Thorac Soc. 2015; 12(5):708-17. doi: 10.1513/AnnalsATS.201410-493OC
Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62(4):360-7. doi: 10.1136/thx.2006.060889
Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros. 2015; 14(4):419-30. doi: 10.1016/j.jcf.2015.03.003
Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013; 68(12):1157-62. doi: 10.1136/thoraxjnl-2013-203204
Jacquot J, Tabary O, Le Rouzic P, Clement A. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol. 2008; 40(9):1703-15. doi: 10.1016/j.biocel.2008.02.002
Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, et al. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial. Contemp Clin Trials. 2013; 36(2):460-9. doi: 10.1016/j.cct.2013.09.004
Silva-Rueda ML, Ramírez-Romero A, Guerra-Maestre LR, Forero-Hollmann ÁM, Lozada-Martínez ID. The need to develop specialized surgical centers: the evidence that surgical diseases cannot wait. Int J Surg. 2021; 92:106036. doi: 10.1016/j.ijsu.2021.106036
Pérez-Fontalvo NM, De Arco-Aragón MA, Jimenez-García JDC, Lozada-Martinez ID. Molecular and computational research in low- and middle-income countries: Development is close at hand. J Taibah Univ Med Sci. 2021; 16(6):948-949. doi: 10.1016/j.jtumed.2021.06.010
Lozada-Martínez ID, Acevedo-Aguilar LM, Mass-Hernández LM, Matta-Rodríguez D, Jiménez-Filigrana JA, Garzón-Gutiérrez KE, et al. Practical guide for the use of medical evidence in scientific publication: Recommendations for the medical student: Narrative review. Ann Med Surg (Lond). 2021; 71:102932. doi: 10.1016/j.amsu.2021.102932
Miranda-Pacheco JA, De Santis-Tamara SA, Parra-Pinzón SL, González-Monterroza JJ, Lozada-Martínez ID. Medical interest groups and work policies as emerging determinants of a successful career: A student perspective - Correspondence. Int J Surg. 2021; 92:106020. doi: 10.1016/j.ijsu.2021.106020
Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022; 99:106589. doi: 10.1016/j.ijsu.2022.106589
Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax. 2013; 68(6):532-9. doi: 10.1136/thoraxjnl-2012-202538
Laguna TA, Williams CB, Brandy KR, Welchlin-Bradford C, Moen CE, Reilly CS, et al. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2015; 14(3):334-40. doi: 10.1016/j.jcf.2014.10.002
Scott LK, Toner R. Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations. Lung. 2017; 195(4):397-401. doi: 10.1007/s00408-017-0024-3
Loh G, Ryaboy I, Skabelund A, French A. Procalcitonin, erythrocyte sedimentation rate and C-reactive protein in acute pulmonary exacerbations of cystic fibrosis. Clin Respir J. 2018; 12(4):1545-1549. doi: 10.1111/crj.12703
Dong K, Moon KM, Chen V, Ng R, Foster LJ, Tebbutt SJ, et al. Identification of novel blood biomarkers of treatment response in cystic fibrosis pulmonary exacerbations by label-free quantitative proteomics. Sci Rep. 2019; 9(1):17126. doi: 10.1038/s41598-019-53759-1
Quinn RA, Lim YW, Mak TD, Whiteson K, Furlan M, Conrad D, et al. Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease. PeerJ. 2016; 4:e2174. doi: 10.7717/peerj.2174
Wagener JS, VanDevanter DR, Konstan MW, Pasta DJ, Millar SJ, Morgan WJ. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatr Pulmonol. 2020; 55(3):828-834. doi: 10.1002/ppul.24577
Magréault S, Roy C, Launay M, Sermet-Gaudelus I, Jullien V. Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions. Clin Pharmacokinet. 2021; 60(4):409-445. doi: 10.1007/s40262-020-00981-0
Ng C, Nadig T, Smyth AR, Flume P. Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2020; 26(6):679-684. doi: 10.1097/MCP.0000000000000730
Houston CJ, Taggart CC, Downey DG. The role of inflammation in cystic fibrosis pulmonary exacerbations. Expert Rev Respir Med. 2020; 14(9):889-903. doi: 10.1080/17476348.2020.1778469
Soret P, Vandenborght LE, Francis F, Coron N, Enaud R, Avalos M, et al. Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis. Sci Rep. 2020; 10(1):3589. doi: 10.1038/s41598-020-60015-4
Skolnik K, Quon BS. Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations. F1000Res. 2018; 7:F1000 Faculty Rev-575. doi: 10.12688/f1000research.13926.1
Castner LM, Zimbric M, Cahalan S, Powell C, Caverly LJ. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria. J Cyst Fibros. 2021; 20(6):926-931. doi: 10.1016/j.jcf.2021.02.001
Espel JC, Palac HL, Cullina JF, Clarke AP, McColley SA, Prickett MH, et al. Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study. BMC Pulm Med. 2017; 17(1):160. doi: 10.1186/s12890-017-0503-6
Schechter MS, VanDevanter DR, Pasta DJ, Short SA, Morgan WJ, Konstan MW, et al. Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Ann Am Thorac Soc. 2018; 15(2):225-233. doi: 10.1513/AnnalsATS.201702-111OC
Cogen JD, Faino AV, Onchiri F, Hoffman LR, Kronman MP, Nichols DP, et al. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Clin Infect Dis. 2021; 73(9):1589-1596. doi: 10.1093/cid/ciab525
Cogen JD, Faino AV, Onchiri F, Hoffman LR, Kronman MP, Nelson M, et al. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Ann Am Thorac Soc. 2020; 17(12):1590-1598. doi: 10.1513/AnnalsATS.202002-179OC
Cogen JD, Faino AV, Onchiri F, Gibson RL, Hoffman LR, Kronman MP, et al. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Ann Am Thorac Soc. 2021; 18(2):266-272. doi: 10.1513/AnnalsATS.202002-176OC
Somayaji R, Russell R, Cogen JD, Goss CH, Nick SE, Saavedra MT, et al. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Ann Am Thorac Soc. 2019; 16(7):853-860. doi: 10.1513/AnnalsATS.201811-773OC
Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland M, et al. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. Am J Respir Crit Care Med. 2020; 201(4):430-437. doi: 10.1164/rccm.201906-1206OC
Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, et al. Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017; 16(5):592-599. doi: 10.1016/j.jcf.2017.04.005
West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, et al. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017; 16(5):600-606. doi: 10.1016/j.jcf.2017.04.003
Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, et al. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021; 204(11):1295-1305. doi: 10.1164/rccm.202102-0461OC
VanDevanter EJ, Heltshe SL, Skalland M, Lechtzin N, Nichols D, Goss CH. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis. J Cyst Fibros. 2021; 20(6):932-936. doi: 10.1016/j.jcf.2021.02.012
Xu X, Abdalla T, Bratcher PE, Jackson PL, Sabbatini G, Wells JM, et al. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J. 2017; 49(4):1601102. doi: 10.1183/13993003.01102-2016
Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev. 2012; 12:CD008319. doi: 10.1002/14651858.CD008319.pub2
Smith S, Rowbotham NJ, Charbek E. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev. 2018; 10(10):CD008319. doi: 10.1002/14651858.CD008319.pub3
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Ivan D. Lozada-Martinez, Fredy L Carreño-Hernández , Deiner Y. Muñoz-Delgado, Álvaro E. Marroquín-Murcia, Juan F. Sánchez-Erazo, Erick L. Rubio-Cano, Lina M. Acosta, John H. Cabrera-Ortiz, Lina M. Dueñas-Triana
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
